Skip to content

May 11, 2026

ChatGPT Image May 7, 2026, 07_11_28 PM

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Clinical Data
Pulsesight reports positive phase 1 data for PST611 in dry AMD

Clinical Data

Pulsesight reports positive phase 1 data for PST611 in dry AMD

PharmaTimes

Early safety and efficacy signals support move into repeatdose phase 2a trial

Read full story

pharminent May 11, 2026 (Last updated: May 11, 2026)

PharmaTimes

Early safety and efficacy signals support move into repeatdose phase 2a trial

Read full story

Post navigation

Previous: Previous Post

Next: BMS’ Sotyktu secures EC approval for psoriatic arthritis

Related Stories

Clinical Data

Viridian data lift prospects for thyroid eye disease drug

pharminent May 5, 2026

Clinical Data

QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS

pharminent May 5, 2026

Clinical Data

Cytokinetics heart drug scores in closely watched trial

pharminent May 5, 2026

You May Have Missed

Regulatory

Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher

pharminent May 11, 2026

Market Access

Deal finally unlocks NHS access to ITF’s Duchenne drug

pharminent May 11, 2026

Regulatory

BMS’ Sotyktu secures EC approval for psoriatic arthritis

pharminent May 11, 2026

Clinical Data

Pulsesight reports positive phase 1 data for PST611 in dry AMD

pharminent May 11, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.